Investor Presentaiton slide image

Investor Presentaiton

• Mithra at a glance Global women's health company O Liege, Belgium Founded in 1999 Listed on Euronext Brussels in 2015: MITRA Innovative Estetrol products О Native estrogen Differentiated benefit/risk profile compared to existing hormone-based solutions ESTELLEⓇ, a new contraceptive DONESTAⓇ, potential treatment for menopausal symptoms & better aging Innovative pipeline expansion Novalon (complex therapeutics) & CDMO Commercial Development/ Performance in H1 2023 -50.5 million EUR net loss 2.6 million EUR Product sales of ESTELLE® 51 million EUR Milestones collected 634,000 MYRINGⓇ vaginal rings produced at our CDMO Dedicated to Mithra as a company transforming women's health Positive Top-line safety results for DONESTAⓇ Phase III (C302) 30 Countries in which our contraceptive pill ESTELLEⓇ is commercialized (+19 vs 2022) 1999 Founded Since 2015 Listed on Euronext Brussels 38 R&D collaborators among 233 dedicated 36 employees Patents covering E4 56% Women employees How we drive our business to lower impact on environment & society (ESG) -22% Reduction in Greenhouse gas emission (target- 55% by 2030) 100% Successful inspections and customer audits 55% Women in leadership posts (CEO N -2) Mithra Investor Presentation - November 2023 6
View entire presentation